Posted by Michael Wonder on 06 Mar 2017
NICE publishes draft guidance on the use of etelcalcetide for secondary hyperparathyroidism
3 March 2017 - The Department of Health has asked the NICE to produce guidance on the use of etelcalcetide hydrochloride in the NHS in England.
Etelcalcetide hydrochloride is recommended as an option for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis, only if:
- treatment with a calcimimetic is indicated but cinacalcet is not suitable and
- the company provides etelcalcetide with the discount agreed in the patient access scheme
Etelcalcetide hydrochloride will be considered at a second Appraisal cCommittee meeting on 6 April 2017.
